Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Akush Ginekol (Sofiia) ; 53(6): 15-21, 2014.
Artigo em Búlgaro | MEDLINE | ID: mdl-25672133

RESUMO

Approximately 7-12% of women in reproductive age are affected by PCOS[2] and 40 to 70 percent of them are overweight contributing to the clinical picture of PCOS and increased reproductive and metabolic disorder. In order to investigate the role of PAl-1 as a possible risk factor for the development of PCOS a group of 67 women with polycystic ovarian disease and 70 healthy controls were investigated for levels of PAl-1 and carriage of the promoter polymorphism 675 4G/5G in gene of PAI-1. The correlation with BMI was checked. The results of the DNA analysis showed a high carriage of polymorphism 675 4G/4G in promoter of PAl-1 gene in women with PCOS but not significant (OR = 1.655; p = 0.141), as well in the total group of the patient (OR =1.474; p>0.05). Serum levels of PAI-1 were significantly higher in total group of patients compared to controls. The levels of PAI-1 is correlated with carriage of 675 4G/5G polymorphism in the gene for PAI-1 (r=0.534; p=0.03) as well as with BMI, like correlation coefficients were higherin the group with PCOS (0.572; p=0.04). Data from the disease history showed a higher percentage of women with reproductive problems: early pregnancy loss 48.5% and infertility 23.2%, significantly higher in the group with PCOS (58.1% compared to 32.4%). The carriers of polymorphism 4G are at greater risk for early pregnancy loss than those with 5G (61.45% as compared to 36.8%), which confirms that carriage of the polymorphism 4G/5G 675 gene PAl-1 has a specific in multifactorial pathogenesis and expression of PCOS.


Assuntos
Aborto Espontâneo/etiologia , Índice de Massa Corporal , Infertilidade Feminina/etiologia , Inibidor 1 de Ativador de Plasminogênio/genética , Síndrome do Ovário Policístico/complicações , Polimorfismo de Nucleotídeo Único , Aborto Espontâneo/sangue , Aborto Espontâneo/genética , Adulto , Feminino , Humanos , Infertilidade Feminina/sangue , Infertilidade Feminina/genética , Inibidor 1 de Ativador de Plasminogênio/sangue , Síndrome do Ovário Policístico/sangue , Síndrome do Ovário Policístico/genética , Gravidez , Regiões Promotoras Genéticas , Fatores de Risco , Adulto Jovem
2.
Akush Ginekol (Sofiia) ; 53(5): 3-9, 2014.
Artigo em Búlgaro | MEDLINE | ID: mdl-25558663

RESUMO

Approximately 7-12% of women in reproductive age are affected by PCOS[2] and 40 to 70 percent of them are overweight contributing to the clinical picture of PCOS and increased reproductive and metabolic disorder. In order to investigate the role of PAl-1 as a possible risk factor for the development of PCOS a group of 67 women with polycystic ovarian disease and 70 healthy controls were investigated for levels of PAI-1 and carriage of the promoter polymorphism 675 4G/5G in gene of PAl-1. The results of the DNA analysis showed a high carriage of polymorphism 675 4G/4G in promoter of PAI-1 gene in women with PCOS but not as significant (OR = 1.6645, p = 0.141). Serum levels of PAI-1 were significantly higher in total group of patients compared to controls. The levels of PAI-1 is correlated with carriage of 675 4G/5G polymorphism in the gene for PAI-1 (R = 0.534, p = 0.03) as well as wih BMI, like correlation coefficients were higher in the group with PCOS (0.572, p = 0.04). Data from the disease history showed a higher percentage of women with reproductive problems: 61.5% (early pregnancy loss and infertility) significantly higher in the group with PCOS (70.1% compared to 54.1%). The carriers of polymorphism 4G are at greater risk for early pregnancy loss than those with 5G (61.45% as compared to 36.8%), which confirms that carriage of the polymorphism 4G/5G 675 gene PAI-1 has a specific in multifactorial pathogenesis and expression of PCOS.


Assuntos
Perda do Embrião/etiologia , Perda do Embrião/genética , Inibidor 1 de Ativador de Plasminogênio/genética , Síndrome do Ovário Policístico/complicações , Síndrome do Ovário Policístico/genética , Polimorfismo de Nucleotídeo Único , Adulto , Índice de Massa Corporal , Perda do Embrião/sangue , Feminino , Humanos , Inibidor 1 de Ativador de Plasminogênio/sangue , Síndrome do Ovário Policístico/sangue , Gravidez , Regiões Promotoras Genéticas , Reprodução , Adulto Jovem
3.
Akush Ginekol (Sofiia) ; 51(4): 3-7, 2012.
Artigo em Búlgaro | MEDLINE | ID: mdl-23234018

RESUMO

Because of the presence of additional confounding factors, such as cervical incompetence or uterine infections, the impact of inherited thrombophilia in women with second infertility has been hard to assess. The evaluation of the significance of the most common inherited thrombophilic factors - Factor V Leiden (FVL), prothrombin gene mutation 20210 G > A (FII), polymorphism (PL) 677 C > T in MTHFR, PL A1/A2 in platelet glycoprotein IIb/IIIa and PAL-1 PL 4G/5G in 35 women with two or more secondary (who have given birth to at least one child) recurrent pregnancy loss (RPL) before 14 weeks of gestation compared to 70 healthy women with no history of RPL and at least one uncomplicated full-term pregnancy, has been performed. Eight out of 35 women with secondary RPL (25.7%) and 6 out of 70 controls (8.6%) have had FVL or FII 20210 G > A (OR: 3.7, 95% CI: 1.05-13.2, p = 0.038). Five (14.3%) women with secondary infertility were carriers for FVL and four (11.4%) for FII 20210 G > A, corresponding to four (5.7%) and two (2.9%) of the women in the control group. The carrier status for MTHFR 677 C > T (TT genotype), PL A1/A2 and PL 4G/5G (4G/4G genotype) was as follows: 11.4%, 28% and 30.8% in patients and 14.3%, 17.1% and 24.3% in controls without significant difference between the groups. Despite of the presence of background factors, an appreciable role of inherited thrombophilia in secondary RPL was established, which enforces thrombophilia testing and management of women with second infertility as well as women with primary RPL.


Assuntos
Aborto Habitual/genética , Infertilidade Feminina/genética , Complicações Hematológicas na Gravidez/genética , Trombofilia/genética , Adolescente , Adulto , Idoso , Fator V/genética , Feminino , Humanos , Infertilidade Feminina/complicações , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Pessoa de Meia-Idade , Mutação , Inibidor 1 de Ativador de Plasminogênio/genética , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/genética , Polimorfismo Genético , Gravidez , Resultado da Gravidez , Protrombina/genética , Trombofilia/complicações , Adulto Jovem
4.
Urologiia ; (2): 58-63, 2007.
Artigo em Russo | MEDLINE | ID: mdl-17578200

RESUMO

Testicular tumors illustrate curable cancer, but 25% patients are resistant to standard therapy. High-dose chemotherapy (HDC) is promising therapy for germ-cell tumors with poor prognosis. HDC and transplantation of autologous stem cells were performed in 13 patients with germ-cell testicular tumors (GTT). In 6 patients of group 1 HDC was first-line treatment in poor prognosis, in 7 patients (group 2) it was a salvage treatment after recurrences. Patients of group 1 had longer mean survival than those of group 2 (31.3 and 11 months, respectively; p = 0.136). Two patients died of HDC complications. Neurological, hematological and other complications occurred. In spite of 50-90% remission after HDC, multicenter prospective randomized trials will give final conclusion on effectiveness of HDC which must be performed in special clinics having many specialists in their staff (urologists, oncologists, chemotherapists, etc.).


Assuntos
Antineoplásicos/administração & dosagem , Neoplasias Embrionárias de Células Germinativas/terapia , Terapia de Salvação , Transplante de Células-Tronco , Neoplasias Testiculares/terapia , Progressão da Doença , Humanos , Masculino , Dose Máxima Tolerável , Neoplasias Embrionárias de Células Germinativas/tratamento farmacológico , Neoplasias Embrionárias de Células Germinativas/cirurgia , Neoplasias Testiculares/tratamento farmacológico , Neoplasias Testiculares/cirurgia , Transplante Autólogo , Resultado do Tratamento
5.
Akush Ginekol (Sofiia) ; 29(1): 32-5, 1990.
Artigo em Búlgaro | MEDLINE | ID: mdl-2372095

RESUMO

The authors compare two methods for antibiotic prophylaxis of infectious-inflammatory complications in cesarean section: 1. Widely distributed mass prophylaxis with penicillin and gentamicin and 2. selective prophylaxis with Azlocillin, performed after determination, of the degree of the risk. 233 cesarean section were included in the study, 122 of which were treated by the first method. 59 out of 11 cesarean sections were evaluated as such with high risk and respectively treated with Azlocillin, but 52 of the women with low risk were not treated with antibiotic. The results show the advantages and economic benefits of the selective antibiotic prophylaxis in cesarean section.


Assuntos
Antibacterianos/uso terapêutico , Cesárea/efeitos adversos , Pré-Medicação/métodos , Infecção da Ferida Cirúrgica/prevenção & controle , Azlocilina/administração & dosagem , Quimioterapia Combinada , Estudos de Avaliação como Assunto , Feminino , Gentamicinas/administração & dosagem , Humanos , Penicilinas/administração & dosagem , Gravidez , Fatores de Risco , Infecção da Ferida Cirúrgica/epidemiologia
6.
Klin Khir (1962) ; (3): 51-3, 1989.
Artigo em Russo | MEDLINE | ID: mdl-2733367

RESUMO

With the use of aerotherapeutical installations, 190 burned children were treated. The overall lethality dropped from 6.2% before the use of the method to 1.6%.


Assuntos
Queimaduras/terapia , Ambiente Controlado , Adolescente , Criança , Pré-Escolar , Humanos , Lactente
8.
Probl Khig ; 1: 53-5, 1975.
Artigo em Búlgaro | MEDLINE | ID: mdl-1236009

RESUMO

The MAC for lead in the workplace atmosphere adopted in Bulgaria, amounting to 0.01 mg/m3, appears to be much lower than abroad. Upon investigation of groups of workers employed in the lead mining and processing industry, working under conditions of lead exposure up to 0.10 mg/m3 and exceeding 0.11 mg/m3, no changes were found in the delta-amino-levulinic acid and coproporphyrin level in the urine--the early signs of lead damage--nor in plumburia mong the workers exposed to lead concentrations up to 0.10 mg/m3 which is a concentration exceeding ten times the MAC accepted in this country. A reassessment of the later on the basis of up-to-date biochemical criteria is deemed necessary.


Assuntos
Poluentes Ocupacionais do Ar , Poluentes Atmosféricos , Chumbo/toxicidade , Ácido Aminolevulínico/urina , Bulgária , Coproporfirinas/urina , Humanos , Chumbo/urina , Concentração Máxima Permitida , Medicina do Trabalho
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...